Skip to main content

Table 1 Clinicopathological characteristics of the patients

From: Significance of a preoperative systemic immune-inflammation index as a predictor of postoperative survival outcomes in gastric cancer

Variables

 

All patients (n = 447)

SII > 395 (n = 280)

SII < 395 (n = 167)

p value

Age, years

Median

67

67

67

0.215

Range

29–89

29–89

39–89

Sex

Male

289

176 (62.9%)

113 (67.7%)

0.302

Female

158

104 (37.1%)

54 (32.3%)

BMI, kg/m2

Median

22.2

21.9

23.1

0.021*

Range

14.4–34.2

14.4–34.2

15.6–30.6

PS

1

233

146 (52.1%)

87 (52.1%)

0.992

> 2

214

134 (47.9%)

80 (47.9%)

Hypertension

Presence

114

77 (27.5%)

37 (22.2%)

0.210

Absence

333

203 (72.5%)

130 (77.8%)

Diabetes mellitus

Presence

64

35 (12.5%)

29 (17.4%)

0.155

Absence

383

245 (87.5%)

138 (82.6%)

Heart disease

Presence

50

30 (10.7%)

20 (12.0%)

0.682

Absence

397

250 (89.3%)

147 (88.0%)

Chronic renal failure

Presence

10

6 (2.1%)

4 (2.4%)

0.862

Absence

437

274 (97.9%)

163 (97.6%)

Tumor location

Upper

145

96 (34.3%)

49 (29.3%)

0.278

Middle/lower

302

184 (65.7%)

118 (70.7%)

CEA, ng/ml

< 5

390

240 (85.7%)

150 (89.8%)

0.202

≥ 5

57

40 (14.3%)

17 (10.2%)

CA19-9, U/ml

< 37

422

261 (93.2%)

161 (96.4%)

0.143

≥ 37

25

19 (6.8%)

6 (3.6%)

Albumin, g/dl

< 3.5

19

17 (6.1%)

2 (1.2%)

0.014*

≥ 3.5

428

263 (93.9%)

165 (98.8%)

CRP, mg/dl

< 0.5

397

245 (87.5%)

152 (91.0%)

0.254

≥ 0.5

50

35 (12.5%)

15 (9.0%)

Neutrophil count, cell/mm3

Median

3690

4145

3060

< 0.001*

Range

1250–15,850

1250–15,850

1420–7630

Lymphocyte count, cell/mm3

Median

1780

1630

2050

< 0.001*

Range

570–4770

570–4770

1050–4640

Monocyte count, cell/mm3

Median

330

340

310

0.008*

Range

50–1400

50–1400

100–750

Platelet count, cell/mm3 × 104

Median

225

245

190

< 0.001*

Range

87–570

570–117

87–314

pT

pT1–3

399

248 (88.6%)

151 (90.4%)

0.539

pT4

48

32 (11.4%)

16 (9.6%)

pN

pN0

323

189 (67.5%)

134 (80.2%)

0.003*

pN+

124

91 (32.5%)

33 (19.8%)

Lymphatic invasion

Presence

169

120 (42.9%)

49 (29.3%)

0.004*

Absence

278

160 (57.1%)

118 (70.6%)

Venous invasion

Presence

138

95 (33.9%)

43 (25.7%)

0.068

Absence

309

185 (66.1%)

124 (74.3%)

Tumor differentiation

Differentiated

231

133 (47.5%)

98 (58.7%)

0.022*

Undifferentiated

216

147 (52.5%)

69 (41.3%)

  1. BMI body mass index, PS physical status, CEA carcinoembryonic antigen, CA19-9 cancer antigen 19-9, CRP C-reactive protein, SII systemic immune inflammation index
  2. *p < 0.05 (significantly different between the high and low SII groups)